CRISPR/Cas9 technology as a useful tool in the study of chronic lymphocytic leukemia.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F23%3A00132849" target="_blank" >RIV/00216224:14740/23:00132849 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

CRISPR/Cas9 technology as a useful tool in the study of chronic lymphocytic leukemia.

Popis výsledku v původním jazyce

Chronic lymphocytic leukemia (CLL) is characterized by genetic heterogeneity and a variety of somatic mutations, the most frequent of which targeting ATM, TP53, NOTCH1, MYD88 and SF3B1 genes. A thorough exploration of these mutations could shed light on the disease etiology, or even lead to the discovery of potential novel drug targets. However, CLL cells extracted from patients do not proliferate ex vivo and thus preclude lengthy experiments, such as CRISPR/Cas9 screening. 76 The aim of this study was to generate stable knockout (ATM, TP53) and knock-in (NOTCH1, SF3B1 and MYD88) CLL cell lines and subsequently use them to investigate unique vulnerabilities specific to these mutations

Název v anglickém jazyce

CRISPR/Cas9 technology as a useful tool in the study of chronic lymphocytic leukemia.

Popis výsledku anglicky

Chronic lymphocytic leukemia (CLL) is characterized by genetic heterogeneity and a variety of somatic mutations, the most frequent of which targeting ATM, TP53, NOTCH1, MYD88 and SF3B1 genes. A thorough exploration of these mutations could shed light on the disease etiology, or even lead to the discovery of potential novel drug targets. However, CLL cells extracted from patients do not proliferate ex vivo and thus preclude lengthy experiments, such as CRISPR/Cas9 screening. 76 The aim of this study was to generate stable knockout (ATM, TP53) and knock-in (NOTCH1, SF3B1 and MYD88) CLL cell lines and subsequently use them to investigate unique vulnerabilities specific to these mutations

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/LX22NPO5102" target="_blank" >LX22NPO5102: Národní ústav pro výzkum rakoviny</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů